JP Morgan Chase
BIB icon

JP Morgan Chase’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

JP Morgan Chase’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,500
Closed -$144K – 7345
2024
Q1 		$144K Hold
2,500
– – ﹤0.01% 5516
2023
Q4 		$143K Hold
2,500
– – ﹤0.01% 5565
2023
Q3 		$120K Hold
2,500
– – ﹤0.01% 5369
2023
Q2 		$130K Buy
2,500
+5
+0.2% +$275 ﹤0.01% 5338
2023
Q1 		$135K Buy
2,495
+504
+25% +$28.4K ﹤0.01% 5280
2022
Q4 		$115K Buy
+1,991
New +$112K ﹤0.01% 5300

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
IMC Chicago
IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
WWM
Westwood Wealth Management Los Angeles, California $255M AUM 54.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCWM
Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase's BIB Position: Q2 2024 in Review

JP Morgan Chase sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2024, closing a stake of 2,500 shares — an estimated $144K sold.

JP Morgan Chase first reported a position in BIB in Q4 2022 and held it in 6 quarters. The position peaked at $144K in Q1 2024. 24 funds tracked by Wall St. Rank hold BIB as of Q2 2024.

  • JP Morgan Chase reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2024 after selling out during the quarter.
  • JP Morgan Chase sold 2,500 ProShares Ultra NASDAQ Biotechnology shares in Q2 2024, an estimated $144K.
  • JP Morgan Chase first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2022 and held it in 6 quarters.
  • JP Morgan Chase's ProShares Ultra NASDAQ Biotechnology position peaked at $144K in Q1 2024.
  • 24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2024.

Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.